So-called Steve Jobs patent reaffirmed after the Patent Office invalidated all 20 claims in the patent last December.
One of Apple's broad patents covering touch-screen technology has been upheld by the US Patent and Trademark Office, a decision that could have a serious impact on cases involving Google and Samsung.
After invalidating US Patent No. 7,479,949 last December, the office issued a re-examination certificate (see below) reaffirming all 20 claims included in the patent, according to a filing last month spotted by Foss Patents. The patent, referred to by many as "the Steve Jobs patent," covers a "touch-screen device, method, and graphical user interface for determining commands by applying heuristics."
Apple filed for the patent in April 2008, listing Apple's co-founder as the chief inventor along with 24 other people. The Patent Office granted the patent just nine months later.
Apple has engaged in a patent war with Google and other handset makers that use the Android operating system. The '949 patent was one of three patents used against Motorola Mobility -- now owned by Google -- in a 2011 patent suit that was tossed out of court last November. The US International Trade Commission, a federal agency with the power to enforce bans on products shipping to the US, ruled in August that Samsung had infringed on the patent, leading to a ban on some of its older products.
It was the second such Apple patent to be deemed completely invalid following a re-examination by the Patent Office. The office issued a similar decision last October for an Apple patent covering the company's rubber-banding bounce effect. However, in that case, the office rejected 17 of 20 claims of Apple's '381 patent, which was a key component in last year's landmark patent lawsuit decision between Apple and Samsung.
Updated at 8:20 p.m. PT to correct outcome of '381 patent examination.
• Eminem is 41, Chris Kirkpatrick of ‘N Sync is 42, Ziggy Marley is 45, Mike Judge (Beavis and Butthead) is 51 and Margot Kidder (Superman) is 65 years old. Click HERE to see who else is celebrating a birthday today.
A Lost Generation of young scientists? U-M grad student voices concern about research funding crunch
Public release date: 17-Oct-2013 [
| E-mail
| Share
]
Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System
Amid federal research cutbacks and sequestration, U-M Medical School offers programs that aim to help young scientists prepare for varied careers
ANN ARBOR, Mich. Alexis Carulli wants to make a difference in fighting human disease. So do the thousands of bright graduate students like her, and recent Ph.D. graduates, working in medical research laboratories around the country.
But with federal scientific research funding flat, eroded by inflation and cut by budget sequestration, Carulli worries for her generation of aspiring biomedical scientists.
In a new article published in the American Journal of Physiology: Gastrointestinal and Liver Physiology, she speaks up about it, to make sure the voice of the young scientist is heard. She describes the potential effect of ongoing instability in research funding -- and highlights the very real impact that today's science funding climate is having on the daily lives and career plans of young researchers-in-training.
"This is an issue that's pervasive, across the country," she says, based on conversations with peers at U-M and at conferences. "The decreased funding levels for science aren't just affecting research right now. If this situation lasts longer, it will have very long-term consequences, because the scientists won't be there."
More of them may head for careers in industry that will use their scientific skills, but won't necessarily focus on discovering entirely new knowledge, she says. Those born overseas and trained here may leave the U.S. to go back to home countries that are pouring money into science funding a sort of reverse "brain drain." And some may decide that the long road of training for a scientific career isn't worth the investment of time and effort, due to uncertainty about funding.
Carulli herself plans to be both a doctor and a scientist a long journey of earning both a medical degree and a Ph.D. through U-M's Medical Scientist Training Program, plus advanced training in a medical residency and fellowship after that.
She's six years in, and hoping that her chosen path -- and full funding for her graduate studies -- will help her weather the storm in science funding. But she can't know for sure.
She also notes that what she heard from her peers is not all doom and gloom. "It was uplifting to see that not everyone had given up," she says. "But the fact that the path to academia is filled with so many obstacles is troubling." As she writes in the paper, "Our success truly is the future of biomedical science."
Supporting students and recent Ph.D.s
Victor DiRita, Ph.D., the associate dean for graduate and postdoctoral studies at the U-M Medical School, says Carulli's concerns resonate with him and his team.
That's why they have created new programs to help graduate students and recent Ph.D.s (called postdoctoral fellows or postdocs) understand the many career paths that biomedical graduates can go down, and the marketable skills that earning a Ph.D. gives them. They work with the Office of Student Success in U-M's Rackham Graduate School, through which Ph.D.'s are awarded.
The U-M Medical School has more than 570 graduate students pursuing masters and Ph.D. degrees, and more than 550 postdocs, training and performing research in its labs. About 30 percent of U-M Medical School Ph.D. graduates go on to academic research careers, while the rest choose to go to teach at small colleges, to industry, or to government and the nonprofit sector.
"Academic positions that are dependent on government funding are limited, so we need to help students understand that their training as a scientist gives them enormous transferrable skills," says DiRita -- first and foremost, their ability to do a "deep dive" on a scientific problem and come up with answers through research. It is essential for each student to develop a "career agility plan" to guide themselves, he says.
"Students need to come in with their eyes wide open," he notes. "Students who are focused on becoming academics really have to work their tails off, because those positions are hard to get. But that level of effort and the expertise that develops from it will contribute to success in many other career paths."
U-M and other schools have increasingly found themselves having to offer "bridge" funding, to help research faculty whose grants are running out and who haven't yet gotten more funding even though their latest grant applications were judged highly worthy. As federal science funds shrink due to cuts and inflation, a smaller percentage of grant applications are getting funded.
Daily impact of funding cuts
With such a high level of uncertainty, Carulli notes in her article, graduate students and postdocs may find themselves unable to pursue a certain experiment right away because their advisor doesn't want to spend their remaining money on expensive supplies that they don't have on hand.
Those who are finishing their initial graduate coursework and looking for a faculty member's laboratory to work in may find that many aren't able to take on new students, due to lack of funding, she says. And those who are finishing Ph.D.s are finding fewer labs can take them on as postdocs.
Carulli studies adult stem cells in the digestive tract as a student in the lab of Linda Samuelson, Ph.D., who is the John A. Williams Professor of Gastrointestinal Physiology in the Department of Molecular and Integrative Physiology, and Associate Director of U-M's Center for Organogenesis.
Samuelson says she's proud of Carulli for gathering and reflecting the concerns that students have, and shares those concerns given the current funding climate. While U-M has weathered the current funding crunch better than other schools, it isn't immune.
"We bring in the brightest young people interested in science, help them define research problems, and support them through the process of discovery and training," she says. "That support depends on our funding for our labs. We make a 4 to 6 year commitment to these students, and we want them to have state-of-the-art technology and important research problems to address. To support that we need sustained funding. It would be a tragedy to lose them."
###
Reference:Am. J. of Physiology: Gastrointestinal and Liver Physiology, DOI: 10.1152/ajpgi.00297.2013 http://ajpgi.physiology.org/content/early/2013/09/27/ajpgi.00297.2013
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
A Lost Generation of young scientists? U-M grad student voices concern about research funding crunch
Public release date: 17-Oct-2013 [
| E-mail
| Share
]
Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System
Amid federal research cutbacks and sequestration, U-M Medical School offers programs that aim to help young scientists prepare for varied careers
ANN ARBOR, Mich. Alexis Carulli wants to make a difference in fighting human disease. So do the thousands of bright graduate students like her, and recent Ph.D. graduates, working in medical research laboratories around the country.
But with federal scientific research funding flat, eroded by inflation and cut by budget sequestration, Carulli worries for her generation of aspiring biomedical scientists.
In a new article published in the American Journal of Physiology: Gastrointestinal and Liver Physiology, she speaks up about it, to make sure the voice of the young scientist is heard. She describes the potential effect of ongoing instability in research funding -- and highlights the very real impact that today's science funding climate is having on the daily lives and career plans of young researchers-in-training.
"This is an issue that's pervasive, across the country," she says, based on conversations with peers at U-M and at conferences. "The decreased funding levels for science aren't just affecting research right now. If this situation lasts longer, it will have very long-term consequences, because the scientists won't be there."
More of them may head for careers in industry that will use their scientific skills, but won't necessarily focus on discovering entirely new knowledge, she says. Those born overseas and trained here may leave the U.S. to go back to home countries that are pouring money into science funding a sort of reverse "brain drain." And some may decide that the long road of training for a scientific career isn't worth the investment of time and effort, due to uncertainty about funding.
Carulli herself plans to be both a doctor and a scientist a long journey of earning both a medical degree and a Ph.D. through U-M's Medical Scientist Training Program, plus advanced training in a medical residency and fellowship after that.
She's six years in, and hoping that her chosen path -- and full funding for her graduate studies -- will help her weather the storm in science funding. But she can't know for sure.
She also notes that what she heard from her peers is not all doom and gloom. "It was uplifting to see that not everyone had given up," she says. "But the fact that the path to academia is filled with so many obstacles is troubling." As she writes in the paper, "Our success truly is the future of biomedical science."
Supporting students and recent Ph.D.s
Victor DiRita, Ph.D., the associate dean for graduate and postdoctoral studies at the U-M Medical School, says Carulli's concerns resonate with him and his team.
That's why they have created new programs to help graduate students and recent Ph.D.s (called postdoctoral fellows or postdocs) understand the many career paths that biomedical graduates can go down, and the marketable skills that earning a Ph.D. gives them. They work with the Office of Student Success in U-M's Rackham Graduate School, through which Ph.D.'s are awarded.
The U-M Medical School has more than 570 graduate students pursuing masters and Ph.D. degrees, and more than 550 postdocs, training and performing research in its labs. About 30 percent of U-M Medical School Ph.D. graduates go on to academic research careers, while the rest choose to go to teach at small colleges, to industry, or to government and the nonprofit sector.
"Academic positions that are dependent on government funding are limited, so we need to help students understand that their training as a scientist gives them enormous transferrable skills," says DiRita -- first and foremost, their ability to do a "deep dive" on a scientific problem and come up with answers through research. It is essential for each student to develop a "career agility plan" to guide themselves, he says.
"Students need to come in with their eyes wide open," he notes. "Students who are focused on becoming academics really have to work their tails off, because those positions are hard to get. But that level of effort and the expertise that develops from it will contribute to success in many other career paths."
U-M and other schools have increasingly found themselves having to offer "bridge" funding, to help research faculty whose grants are running out and who haven't yet gotten more funding even though their latest grant applications were judged highly worthy. As federal science funds shrink due to cuts and inflation, a smaller percentage of grant applications are getting funded.
Daily impact of funding cuts
With such a high level of uncertainty, Carulli notes in her article, graduate students and postdocs may find themselves unable to pursue a certain experiment right away because their advisor doesn't want to spend their remaining money on expensive supplies that they don't have on hand.
Those who are finishing their initial graduate coursework and looking for a faculty member's laboratory to work in may find that many aren't able to take on new students, due to lack of funding, she says. And those who are finishing Ph.D.s are finding fewer labs can take them on as postdocs.
Carulli studies adult stem cells in the digestive tract as a student in the lab of Linda Samuelson, Ph.D., who is the John A. Williams Professor of Gastrointestinal Physiology in the Department of Molecular and Integrative Physiology, and Associate Director of U-M's Center for Organogenesis.
Samuelson says she's proud of Carulli for gathering and reflecting the concerns that students have, and shares those concerns given the current funding climate. While U-M has weathered the current funding crunch better than other schools, it isn't immune.
"We bring in the brightest young people interested in science, help them define research problems, and support them through the process of discovery and training," she says. "That support depends on our funding for our labs. We make a 4 to 6 year commitment to these students, and we want them to have state-of-the-art technology and important research problems to address. To support that we need sustained funding. It would be a tragedy to lose them."
###
Reference:Am. J. of Physiology: Gastrointestinal and Liver Physiology, DOI: 10.1152/ajpgi.00297.2013 http://ajpgi.physiology.org/content/early/2013/09/27/ajpgi.00297.2013
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
(Reuters) - Blackstone Group LP, the largest publicly listed alternative asset manager, said on Thursday that its third-quarter earnings increased by 3 percent year-on-year as its fee revenue and profits from sales of its holdings rose.
Blackstone, whose investments include The Weather Channel, Pinnacle Foods and SeaWorld Entertainment Inc, said economic net income (ENI), a metric of its profitability that takes into account the mark-to-market valuation of its portfolio, was $640.2 million, up from $621.8 million in the third quarter of 2012.
This translates into ENI per unit of 56 cents, slightly higher than the average 55 cents forecast by analysts in a Thomson Reuters poll.
Distributable earnings, which show actual cash that is available to pay dividends, rose in the third quarter 59 percent to $312.7 million.
Total assets under management hit a record $248 billion as of the end of September, up 21 percent year-on-year. Fee-earning assets under management rose 12 percent to $188.7 billion.
Blackstone declared a quarterly distribution of 23 cents per common unit.
(Reporting by Greg Roumeliotis in New York; Editing by Gerald E. McCormick)
Zombies have reached their pop culture peak. From books, comic books, movies, TV shows and apps, it's hard to avoid the legions of undead — well, except in real life.
For now at least, the dead stay put outside of fictitious setups. But just in case humanity ever finds itself facing a genuine zombie menace, the gang at "MythBusters" is putting zombie lore to the test.
Actually, as evidenced by the exclusive clip Discovery provided TODAY, they'll be putting humans to the test, to see if we stand a chance when it comes to surviving a zombie invasion.
The sneak peek reveals that the "MythBusters: Zombie Special" packs a new version of the usual disclaimer that kicks off the show.
"WARNING! The following show contains gruesome images of the undead being hacked, whacked and smacked," it reads. "Viewer discretion is advised. In addition, do not try what you are about to see at home — all zombies used in this show were undead experts."
Good to know.
To make sure the test is legit — or as legit as a test about a zombie apocalypse can be — "MythBusters" enlisted the help of Greg Nicotero from KNB EFX Group, otherwise known as the special effects house behind "Day of the Dead," "Amy of Darkness," "The Walking Dead," and the not-so-zombie packed show, "Breaking Bad." Nicotero covered the basics of what zombies can and can't do.
"We use the scene in 'Night of the Living Dead,' the cemetery (scene), as our holy grail for zombie movement," he explained. "They're not very quick. They're attracted to sound. ... (And) they're not very smart. Generally speaking, you've just go to make sure you don't get overrun by too many of them."
But that's just what the "MythBusters" Built Team plans to do. With 150 volunteers playing the part of the brain munchers, they'll attempt to see if escape is possible.
You can watch them set up the task in the sneak peek, but you'll have to tune in to find out it if it's a victory for Team Human.
"The Walking Dead's" Michael Rooker (who played Merle Dixon, RIP) will also join the fun on "MythBusters" on Oct. 17 at 10 p.m. on Discovery.
Like Puppet, Chef, and Ansible, Salt is an open source server management and automation solution with commercial, officially supported options. Based on command-line-driven server and client services and utilities, Salt is primarily focused on Linux and Unix server management, though it offers significant Windows management capabilities as well. While Salt may look simple on its face, it's surprisingly powerful and extensible, and it has been designed to handle extremely large numbers of clients.
Salt uses a push method of communication with clients by default, though there's also a means to use SSH rather than locally installed clients. Using the default push method, the clients don't actively check in with a master server; rather, the master server reaches out to control or modify each client based on commands issued manually or through scheduling. But again, Salt can also operate in the other direction, with clients querying the master for updates. Salt functions asynchronously, and as such, it's very fast. It also incorporates an asynchronous file server for file deployments.
Female hormones key to breast and ovarian cancer in BRCA gene carriers
Public release date: 16-Oct-2013 [
| E-mail
| Share
]
Contact: Clare Ryan clare.ryan@ucl.ac.uk 44-020-310-83846 University College London
Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.
The study, carried out by researchers at the UCL Department of Women's Cancer, found that abnormal levels of female hormones in the bloodstream could be the answer. The findings have already led to more research into novel ways of preventing cancers in women at risk.
According to the results of the study, women with BRCA1 or BRCA2 mutations are exposed to different levels of the female hormones oestradiol and progesterone, which are already known to be risk-factors for breast and ovarian cancer.
The findings indicate that BRCA carriers have abnormal hormone regulation, possibly due to a mechanism linked to the altered BRCA genes in carriers' ovaries. It is also possible that BRCA gene alterations change the sensitivity of tissues to hormones. More research into these mechanisms is needed.
The findings open up a new window of opportunity to prevent breast and ovarian cancer in BRCA mutation carriers. The authors anticipate that following further lab work, an existing drug currently used to treat osteoporosis could be suitable for use in a clinical trial of breast cancer prevention in BRCA1/2 carriers.
Professor Martin Widschwendter, Head of the UCL Women's Cancer Department who led the research said: "We have shown for the first time that cancer risk in BRCA1 and BRCA2 carriers is not just caused by local defects in the ability of cells to repair themselves."
He added: "An additional, systemic problem abnormal levels of female hormones in the bloodstream and altered downstream effects is the likely explanation as to why BRCA1/2 mutations carriers develop breast and ovarian cancer rather than other cancers."
In the study, researchers analysed 1966 uterus lining thickness measurements, taken using ultrasound scans. They compared 1573 measurements in women negative for both mutations with 203 measurements from carriers of BRCA1 and 190 with BRCA2.
Because the thickness of the uterus lining, or endometrium, is known to depend at least partly on the levels of female hormones, researchers then measured the concentration of these hormones in the participants' bloodstreams.
Not only did they find that carriers of BRCA1/2 did have higher concentrations of female hormones, they also found that differences in the levels of hormones correlated with the differences in the thickness of the endometrium in the second half of the menstrual cycle.
Based on these findings, research has already begun into how estrogens affect the Fallopian tubes, as this is where the majority of "ovarian" cancers in BRCA1/2 carriers actually start. The goal is to design drugs that might prevent the carcinogenic effect of high concentrations of estrogens in the Fallopian tube.
The other female hormone, progesterone, is known to trigger molecular changes in breast cells, specifically the production of the growth factor protein RANKL, which lead to cancer. Blocking and neutralizing RANKL by applying an antibody is an entire new concept to prevent breast cancer and will be tested in women with BCRCA1/2 mutations by Prof Widschwendter's team after further laboratory work.
Dr Adam Rosenthal, also from the UCL Department of Women's Cancer and one of the study co-authors, said: "Many women with BRCA1 or BRCA2 mutations decide to have their breasts and ovaries removed because of their high-risk status. Clearly this is a drastic measure and there is an urgent need to develop less extreme approaches for cancer prevention in such women."
Helena Morrisey, chairman of The Eve Appeal is delighted with the news. "We are proud to have funded this research which is a fantastic step towards our ultimate goal of prevention of women's cancer. We are hopeful that based on this study and future work funded by the Eve Appeal, women at high risk won't have to go through what Angelina Jolie went through."
###
The research was funded by The Eve Appeal with contributions from the European Union, Cancer Research UK and the US National Institutes of Health.
Notes for Editors
1. For more information or to speak to Professor Martin Widschwendter, please contact Clare Ryan in the UCL Media Relations Office on tel: +44 (0)20 3108 3846, mobile: +44 07747 556 056, out of hours +44 (0)7917 271 364, e-mail: clare.ryan@ucl.ac.uk
2. 'The sex hormone system in carriers of BRCA1/2 mutations: a case-control study' is published online today in Lancet Oncology. For copies of the paper please contact UCL Media Relations.
About UCL (University College London)
Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender and the first to provide systematic teaching of law, architecture and medicine.
We are among the world's top universities, as reflected by our performance in a range of international rankings and tables. According to the Thomson Scientific Citation Index, UCL is the second most highly cited European university and the 15th most highly cited in the world.
UCL has nearly 25,000 students from 150 countries and more than 9,000 employees, of whom one third are from outside the UK. The university is based in Bloomsbury in the heart of London, but also has two international campuses UCL Australia and UCL Qatar. Our annual income is more than 800 million.
http://www.ucl.ac.uk | Follow us on Twitter @uclnews | Watch our YouTube channel YouTube.com/UCLTV
About The Eve Appeal
The Eve Appeal was publicly launched in 2005 to help save women's lives by funding research into gynaecological cancers and raising awareness of the diseases. To date The Eve Appeal has donated over 5 million to research but there is still much to do. Much of the research work now under way will not be completed for some years and continued funding is essential if its early promise is to be fulfilled.
For the future The Eve Appeal continues to work towards its vision of a world where fewer women develop and significantly more women survive gynaecological cancers.
http://www.eveappeal.org.uk
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Female hormones key to breast and ovarian cancer in BRCA gene carriers
Public release date: 16-Oct-2013 [
| E-mail
| Share
]
Contact: Clare Ryan clare.ryan@ucl.ac.uk 44-020-310-83846 University College London
Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.
The study, carried out by researchers at the UCL Department of Women's Cancer, found that abnormal levels of female hormones in the bloodstream could be the answer. The findings have already led to more research into novel ways of preventing cancers in women at risk.
According to the results of the study, women with BRCA1 or BRCA2 mutations are exposed to different levels of the female hormones oestradiol and progesterone, which are already known to be risk-factors for breast and ovarian cancer.
The findings indicate that BRCA carriers have abnormal hormone regulation, possibly due to a mechanism linked to the altered BRCA genes in carriers' ovaries. It is also possible that BRCA gene alterations change the sensitivity of tissues to hormones. More research into these mechanisms is needed.
The findings open up a new window of opportunity to prevent breast and ovarian cancer in BRCA mutation carriers. The authors anticipate that following further lab work, an existing drug currently used to treat osteoporosis could be suitable for use in a clinical trial of breast cancer prevention in BRCA1/2 carriers.
Professor Martin Widschwendter, Head of the UCL Women's Cancer Department who led the research said: "We have shown for the first time that cancer risk in BRCA1 and BRCA2 carriers is not just caused by local defects in the ability of cells to repair themselves."
He added: "An additional, systemic problem abnormal levels of female hormones in the bloodstream and altered downstream effects is the likely explanation as to why BRCA1/2 mutations carriers develop breast and ovarian cancer rather than other cancers."
In the study, researchers analysed 1966 uterus lining thickness measurements, taken using ultrasound scans. They compared 1573 measurements in women negative for both mutations with 203 measurements from carriers of BRCA1 and 190 with BRCA2.
Because the thickness of the uterus lining, or endometrium, is known to depend at least partly on the levels of female hormones, researchers then measured the concentration of these hormones in the participants' bloodstreams.
Not only did they find that carriers of BRCA1/2 did have higher concentrations of female hormones, they also found that differences in the levels of hormones correlated with the differences in the thickness of the endometrium in the second half of the menstrual cycle.
Based on these findings, research has already begun into how estrogens affect the Fallopian tubes, as this is where the majority of "ovarian" cancers in BRCA1/2 carriers actually start. The goal is to design drugs that might prevent the carcinogenic effect of high concentrations of estrogens in the Fallopian tube.
The other female hormone, progesterone, is known to trigger molecular changes in breast cells, specifically the production of the growth factor protein RANKL, which lead to cancer. Blocking and neutralizing RANKL by applying an antibody is an entire new concept to prevent breast cancer and will be tested in women with BCRCA1/2 mutations by Prof Widschwendter's team after further laboratory work.
Dr Adam Rosenthal, also from the UCL Department of Women's Cancer and one of the study co-authors, said: "Many women with BRCA1 or BRCA2 mutations decide to have their breasts and ovaries removed because of their high-risk status. Clearly this is a drastic measure and there is an urgent need to develop less extreme approaches for cancer prevention in such women."
Helena Morrisey, chairman of The Eve Appeal is delighted with the news. "We are proud to have funded this research which is a fantastic step towards our ultimate goal of prevention of women's cancer. We are hopeful that based on this study and future work funded by the Eve Appeal, women at high risk won't have to go through what Angelina Jolie went through."
###
The research was funded by The Eve Appeal with contributions from the European Union, Cancer Research UK and the US National Institutes of Health.
Notes for Editors
1. For more information or to speak to Professor Martin Widschwendter, please contact Clare Ryan in the UCL Media Relations Office on tel: +44 (0)20 3108 3846, mobile: +44 07747 556 056, out of hours +44 (0)7917 271 364, e-mail: clare.ryan@ucl.ac.uk
2. 'The sex hormone system in carriers of BRCA1/2 mutations: a case-control study' is published online today in Lancet Oncology. For copies of the paper please contact UCL Media Relations.
About UCL (University College London)
Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender and the first to provide systematic teaching of law, architecture and medicine.
We are among the world's top universities, as reflected by our performance in a range of international rankings and tables. According to the Thomson Scientific Citation Index, UCL is the second most highly cited European university and the 15th most highly cited in the world.
UCL has nearly 25,000 students from 150 countries and more than 9,000 employees, of whom one third are from outside the UK. The university is based in Bloomsbury in the heart of London, but also has two international campuses UCL Australia and UCL Qatar. Our annual income is more than 800 million.
http://www.ucl.ac.uk | Follow us on Twitter @uclnews | Watch our YouTube channel YouTube.com/UCLTV
About The Eve Appeal
The Eve Appeal was publicly launched in 2005 to help save women's lives by funding research into gynaecological cancers and raising awareness of the diseases. To date The Eve Appeal has donated over 5 million to research but there is still much to do. Much of the research work now under way will not be completed for some years and continued funding is essential if its early promise is to be fulfilled.
For the future The Eve Appeal continues to work towards its vision of a world where fewer women develop and significantly more women survive gynaecological cancers.
http://www.eveappeal.org.uk
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Share